Patents
Literature
2468 results about "Antibody" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An antibody (Ab), also known as an immunoglobulin (Ig), is a large, Y-shaped protein produced mainly by plasma cells that is used by the immune system to neutralize pathogens such as pathogenic bacteria and viruses. The antibody recognizes a unique molecule of the pathogen, called an antigen, via the fragment antigen-binding (Fab) variable region. Each tip of the "Y" of an antibody contains a paratope (analogous to a lock) that is specific for one particular epitope (similarly, analogous to a key) on an antigen, allowing these two structures to bind together with precision. Using this binding mechanism, an antibody can tag a microbe or an infected cell for attack by other parts of the immune system, or can neutralize its target directly (for example, by inhibiting a part of a microbe that is essential for its invasion and survival). Depending on the antigen, the binding may impede the biological process causing the disease or may activate macrophages to destroy the foreign substance. The ability of an antibody to communicate with the other components of the immune system is mediated via its Fc region (located at the base of the "Y"), which contains a conserved glycosylation site involved in these interactions. The production of antibodies is the main function of the humoral immune system.
Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof
PendingUS20260001964A1Organic active ingredientsHybrid immunoglobulinsAntigen Binding FragmentCell Surface Antigens
The present invention provides a combination of (i) an immune checkpoint modulator and (ii) a T-cell redirecting multifunctional antibody, or an antigen binding fragment thereof, for use in therapeutic treatment of a cancer disease. The T-cell redirecting multifunctional antibody comprises (a) a specificity against a T cell surface antigen; (b) a specificity against a cancer- and / or tumor-associated antigen; and (c) a binding site for human FcγRI, FcγRIIa and / or FcγRIII, wherein the antibody, or the antigen binding fragment thereof, binds with a higher affinity to human FcγRI, FcγRIIa and / or FcγRIII than to human FcγRIIb.
Owner:LINDIS BIOTECH GMBH
Sample pretreatment automation method for flow detection
The invention provides a sample pretreatment automation method for flow cytometry, and belongs to the technical field of sample pretreatment for flow cytometry. A biological sample to be detected is collected and placed in a collection tube containing an EDTA-K2 anticoagulant for pretreatment; an automatic pipetting system is used for carrying out incubation reaction on an anticoagulant whole blood sample and an intelligent matching fluorescence labeling antibody mixed solution, and a double-layer game optimization verification system is used for verifying the rationality of an antibody adding proportion and reaction condition parameters; carrying out fluorescence characteristic readability index prediction on the incubated cell suspension by adopting an intelligent dilution parameter regulator model, dynamically adjusting hemolysis parameters and suspension conditions, and adding 1 * hemolysin working solution by using an automatic liquid adding device to carry out hemolysis treatment so as to finish pretreatment; the technical problems that in the pretreatment process of flow cytometry detection samples, parameters are often based on artificial experience, and the reproducibility and standardization degree of detection results are insufficient are solved.
Owner:QINGDAO RAISECARE BIOTECHNOLOGY CO LTD
Software development automation test case generation system based on artificial intelligence
The invention belongs to the technical field of software development and testing, and discloses an artificial intelligence-based software development automatic test case generation system, which is characterized in that an immune heuristic case self-repairing module is adopted, defects are regarded as antigens, antibody cases capable of being self-updated are generated by using a clone selection algorithm, and a gene rearrangement mechanism is automatically triggered when an interface is changed, so that the test efficiency is improved. The details of the use case are adjusted while the core detection logic is reserved; compared with a traditional method, the mechanism can realize use case dynamic adaptation without manual intervention, the maintenance workload is remarkably reduced, and the method is particularly suitable for a complex software system with frequent iteration; the space-time coupling test scene generation engine fuses dynamic scenes such as interaction and state transition of a module and short-time operation after precise coverage login by using a space-time convolutional network; the cross-dimension holographic use case synthesis module integrates multi-source data such as codes, hardware and user behaviors through tensor decomposition to generate a composite use case; functions and performance of software in a complex scene can be comprehensively verified, and test blind areas are remarkably reduced.
Owner:SHANDONG BIAOFAN INFORMATION TECH CO LTD
Composition for detecting NAD < + > and application thereof
The invention specifically discloses a composition for detecting NAD < + > and application thereof, and relates to the technical field of biological detection. According to the composition for detecting NAD < + >, the composition comprises an NAD < + > binding protein fragment A connected with an Fc tag, an NAD < + > binding protein fragment B and a connecting peptide, the detection result is accurate and reliable, and meanwhile the technical difficulty, uncertainty and high cost faced by antibody screening in a traditional method are avoided.
Owner:HEFEI KNATURE BIO PHARM CO LTD
Mouse hepatitis virus antibody or antigen binding fragment thereof as well as preparation method and application thereof
ActiveCN121005775AGenetically modified cellsImmunoglobulins against virusesAntigenAntigen Binding Fragment
The invention belongs to the technical field of biology, and particularly relates to a mouse hepatitis virus antibody or an antigen binding fragment thereof as well as a preparation method and application thereof. The antibody or the antigen binding fragment thereof can specifically recognize and bind to the mouse hepatitis virus or the NSP3 protein thereof, and has good affinity with the mouse hepatitis virus or the NSP3 protein thereof; the kit can be used for preparing products for diagnosing, preventing and / or treating mouse hepatitis virus infection or diseases caused by the mouse hepatitis virus infection, detecting existence or level of mouse hepatitis virus or NSP3 protein in a sample, screening medicines for preventing and / or treating the mouse hepatitis virus infection or the diseases caused by the mouse hepatitis virus infection, and carrying out basic research and / or vaccine development.
Owner:GUANGZHOU NAT LAB
Influenza A virus and influenza B virus sandwich method detection reagent and application thereof
The invention provides an influenza A / B virus sandwich method detection reagent. The influenza A / B virus sandwich method detection reagent comprises a pair of influenza A virus antibodies and a pair of influenza B virus antibodies, the pair of influenza A virus antibodies comprises a labeled antibody 19C7 and a coated antibody 27H4, the heavy chain amino acid sequence of the 19C7 antibody is SEQ ID NO: 1, and the light chain amino acid sequence of the 19C7 antibody is SEQ ID NO: 2; the heavy chain amino acid sequence of the 27H4 antibody is SEQ ID NO: 9, and the light chain amino acid sequence of the 27H4 antibody is SEQ ID NO: 10; the pair of influenza B virus antibodies comprises a labeled antibody 10G11 and a coated antibody 23E2, the heavy chain amino acid sequence of the 10G11 antibody is SEQ ID NO: 17, and the light chain amino acid sequence of the 10G11 antibody is SEQ ID NO: 18; the heavy chain amino acid sequence of the 23E2 antibody is SEQ ID NO: 25, and the light chain amino acid sequence of the 23E2 antibody is SEQ ID NO: 26. The sandwich method detection reagent has extremely high specificity and sensitivity.
Owner:XIAMEN KANGJI BIOTECHNOLOGY CO LTD +1
Fluorescence colorimetric sensor for detecting circulating tumor cells and preparation method of fluorescence colorimetric sensor
PendingCN120610002AColor/spectral properties measurementsBiological testingUltraviolet absorbanceTumor cells
The invention discloses a fluorescent colorimetric sensor for detecting circulating tumor cells and a preparation method of the fluorescent colorimetric sensor. The preparation method comprises the following steps: S4, adding a prepared detection antibody modified with horse radish peroxidase and used for detecting the circulating tumor cells, and incubating; s5, adding a Tris buffer solution and a H2O2 solution, and incubating; s6, preparing an EuMOF nanoflower solution; and S7, adding the EuMOF nanoflower solution and 3, 3 ', 5, 5'-tetramethyl benzidine to react, detecting the fluorescence intensity in the presence of circulating tumor cells with different concentrations by using a luminoscope, detecting the ultraviolet absorbance value in the presence of circulating tumor cells with different concentrations by using a multifunctional microplate reader, and constructing a fluorescence intensity-concentration working curve and an ultraviolet absorbance value-concentration working curve. The method is used for qualitative and quantitative analysis and detection of the circulating tumor cells, realizes bimodal signal response to the circulating tumor cells, and has high sensitivity and simplicity and convenience in operation.
Owner:GANNAN MEDICAL UNIV
Antibody aiming at staphylococcus aureus enterotoxin B and application thereof
ActiveCN120988117AAntibacterial agentsGenetically modified cellsStaphylococcus aureus enterotoxin BStaphyloccocus aureus
The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.
Owner:CHONGQING YUANLUN BIOTECH
Batching optimizing and adjusting system for phage type antibiotic-free feed additive
ActiveCN121354727AChemical property predictionMeasurement devicesHealth indexBiochemical engineering
The invention relates to the technical field of feed ingredient optimization, in particular to an ingredient optimization and adjustment system for a phage type antibiotic-free feed additive. Comprising the following steps: acquiring multi-dimensional environmental data and antibody content indexes and stress state information of individuals; determining a health index according to the antibody content index and the stress state information; performing batching delay analysis according to the change of the health index, and determining a lag moment; determining an effect coefficient in combination with the lagging time and the health index, determining the influence degree of the environmental data of each dimension on the batching effect, and screening to obtain an influence environmental dimension in combination with the influence degree of the environmental data of all dimensions on the batching effect and the predicted value of the environmental data in the next batch; and adjusting the ratio of additives in the same feeding stage in the next batch based on the influence environment dimension. According to the method, the ingredient adjustment logic can be optimized, and the adaptability of ingredients in a multi-dimensional complex scene is improved.
Owner:CHANGCHUN VOCATIONAL INST OF TECH
Immunosensor for detecting cytokine interferon gamma through electrochemiluminescence as well as preparation method and application of immunosensor
The invention discloses an immunosensor for detecting cytokine interferon gamma through electrochemiluminescence as well as a preparation method and application of the immunosensor. The immunosensor comprises a three-electrode system consisting of an immunoelectrode, a reference electrode and a counter electrode, the immunoelectrode is a VMSF modified electrode confined to cerium dioxide nano enzyme and platinum nano particles, and is obtained by covalently immobilizing an IFN-gamma antibody and closing a non-specific site; when the immunosensor is used for detection, a solution containing luminol is used as an electrolyte. The CeO2 and the PtNPs which are confined in the nano channel show a remarkable synergistic catalysis effect. Compared with direct modification on a plate electrode, CeO2-PtNPs has higher catalytic activity and stability. The sensor provided by the invention is used for INF-gamma detection, has the advantages of high sensitivity, low detection limit and wide detection range, does not need complex pretreatment and separation processes during detection, reduces the detection cost, is simple to operate, and is suitable for large-scale application.
Owner:HANGZHOU FIRST PEOPLES HOSPITAL
Cetirizine monoclonal antibody, nucleic acid molecule, carrier, detection kit and application thereof
The invention belongs to the technical field of colloidal gold immunochromatography, and relates to a cetirizine monoclonal antibody, a nucleic acid molecule, a carrier, a detection kit and application thereof. The cetirizine monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a VH-CDR1, a VH-CDR2 and a VH-CDR3, the light chain variable region comprises a VL-CDR1, a VL-CDR2 and a VL-CDR3, the sequence of the VH-CDR1 is as shown in SEQ ID NO.1, the sequence of the VH-CDR2 is as shown in SEQ ID NO.2, and the sequence of the VH-CDR3 is as shown in SEQ ID NO.3. The invention further discloses a preparation method of the cetirizine monoclonal antibody. The monoclonal antibody provided by the invention has high sensitivity to cetirizine, the lowest detection limit is 0.007 ng / mL, the quantitative range is 0.017-0.282 ng / mL, and the specificity is strong.
Owner:THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
A novel antibody binding specifically to nptxr and use thereof
PCT designated stageWO2025219100A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntineoplastic agentsAntigenHeavy chain
The present invention is directed to an isolated antibody or antigen binding fragment thereof binding specifically to human NPTXR with the amino acid sequence of SQ ID NO: 1, wherein the isolated antibody or antigen binding fragment comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 4; HCDR2 comprises the amino acid sequence of SEQ ID NO: 5; and HCDR3 comprises the amino acid sequence of SEQ ID NO: 6; and wherein LCDR1 comprises the amino acid sequence of SEQ ID NO: 7; LCDR2 comprises the amino acid sequence of SEQ ID NO: 8; and LCDR3 comprises the amino acid sequence of SEQ ID NO: 9.
Owner:YMMUNOBIO AG
In-situ detection method of protein and phosphoinositide compound in tissue level
The invention relates to the technical field of biological detection, and discloses an in-situ detection method for the tissue level of a protein and phosphoinositide compound, which comprises the following steps: providing a to-be-detected tissue sample containing the protein and phosphoinositide compound; incubating the sample to be detected by using a primary antibody mixture; incubating a product obtained in the previous step by using a second antibody mixture containing a PLA probe, and reacting to obtain circular DNA (Deoxyribose Nucleic Acid); carrying out in-situ amplification by taking the circular DNA as a template; and acquiring and analyzing a signal of the detection probe. According to the method, the interaction between the protein and the phosphoinositide compound can be specifically detected in situ at the tissue level, the actual state of the protein and the phosphoinositide compound in the physiological and pathological processes of cells can be more truly reflected by the technology, and more accurate information is provided for researching the function and regulation mechanism of the protein and the phosphoinositide compound; wide application prospects are realized.
Owner:SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY
Recombinant protein for detecting para-tumor Yo antibody through CBA method and application
The invention discloses a recombinant protein for detecting a para-tumor Yo antibody through a CBA method and application, and belongs to the technical field of biomedical engineering.The amino acid sequence of the recombinant protein sequentially comprises a secretory signal peptide, a CDR2 protein partial sequence, a CDR2L protein partial sequence, a transmembrane region and a fluorescent label, and the secretory signal peptide is human albumin signal peptide ALB; the transmembrane region is a CD8a hinge; and the fluorescent label is mCherry. A novel recombinant protein which can be stably over-expressed on a cell membrane of an eukaryotic cell is constructed by intercepting specific partial sequences of CDR2 protein and CDR2L protein and redesigning and fusing a fluorescent label by using a secretory signal peptide, a transmembrane sequence and a connecting peptide, and the recombinant protein retains respective core antigen regions of the CDR2 protein and the CDR2L protein, so that the specific partial sequences of the CDR2 protein and the CDR2L protein can be stably over-expressed on the cell membrane of the eukaryotic cell. The kit can effectively overcome the defects in the aspects of sensitivity and specificity, and when a CBA method is adopted for detection, the detection rate of the para-tumor Yo antibody can be remarkably increased, and the false positive rate is reduced, so that the requirements of clinical detection are better met.
Owner:CHENGDU HAIERYUNYIN MEDICAL LAB CO LTD
Tumor cell vaccine as well as preparation method and application thereof
The invention provides a tumor cell vaccine as well as a preparation method and application thereof. The preparation method comprises the following steps: acquiring and culturing tumor cells; enabling the cell membrane of the tumor cell to express a targeting antibody by utilizing a gene vector infection or gene editing technology, and enabling the targeting antibody to be used for enabling the tumor vaccine to be combined with the dendritic cell; performing overexpression of tumor specific protein on the cell membrane surface of the tumor cell by using a gene vector infection or gene editing technology; a nucleic acid substance of a target protein is wrapped by lipid nanoparticles to form a vaccine framework, and the nucleic acid substance can enable target cells to express directional chemotactic molecules; wherein the directed chemotactic molecule is used for transferring the dendritic cells to lymph nodes; the target vaccine is obtained by wrapping the vaccine framework with the cell membranes of the tumor cells, lymph node homing of the dendritic cells can be promoted, and the antigen presentation efficiency is increased and the immune effect is enhanced through tumor specific protein carried by the target vaccine and assisted by an immunologic adjuvant.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Antibody against claudin 18A2 and use thereof
ActiveUS12415853B2Immunoglobulin superfamilyPeptide/protein ingredientsAntigenAntigen Binding Fragment
Provided are an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, a derivative comprising said antibody or antigen-binding fragment thereof, a pharmaceutical composition, and related use of said antibody or antigen-binding fragment thereof for treating, diagnosing and detecting cancers.
Owner:QILU PHARMA CO LTD
Antibody drug conjugate property prediction method based on multi-modal fusion
The invention provides an antibody drug conjugate property prediction method based on multi-modal fusion, and belongs to the field of bioinformatics. The method comprises the following steps: firstly, explicitly modeling sequence position information through sine position coding; secondly, introducing a bidirectional cross attention mechanism to establish interaction between a light chain and a heavy chain and alignment between an antigen and an antibody; thirdly, the integrated graph neural network reconstructs the adjacency relation according to the attention weight, and topological features are extracted; and finally, in combination with a double-stage self-adaptive refining module, two-stage treatment of alignment and refining is realized, and each modal feature contribution is adjusted in a self-adaptive manner. And meanwhile, the sequence robustness is improved through Mask perception feature extraction, and the interpretability analysis of the key binding sites is realized through the attention weight. The method can significantly improve the prediction accuracy, and can be widely applied to cancer targeted therapy and drug design optimization.
Owner:LUDONG UNIVERSITY
Recombinant protein for improving curative effect of ADC drug and application of recombinant protein
PendingCN121159711APolypeptide with localisation/targeting motifAntibody mimetics/scaffoldsCell membraneProtein structure
The invention relates to the technical field of biology, and particularly discloses a recombinant protein for improving the curative effect of an ADC drug and application of the recombinant protein. The recombinant protein comprises a tumor cell surface targeting structure, a cell transmembrane structure and toxin molecules, the toxin molecule is connected and fused with the tumor cell surface targeting structure and / or the cell transmembrane structure; the tumor cell surface targeting structure is a protein structure capable of being specifically combined with a tumor cell surface target spot; and the cell penetrating structure is a protein structure for mediating the recombinant protein to penetrate through a cell membrane to enter the cell. The tumor cell surface targeting structure is used for specifically recognizing a target cell surface target spot, the killing activity of a conventional antibody is brought into play, then toxin molecules are brought into tumor cells through the cell transmembrane structure, toxin is released, the tumor killing effect is achieved, the ADC drug curative effect is improved, and the ADC drug application prospect is wide. The transmembrane efficiency of the cell transmembrane structure can be improved to 50-90%, so that the traditional ADC drug treatment window is improved.
Owner:HEBEI SHENYU BIOTECHNOLOGY CO LTD
Single domain antibodies for inhibiting neutrophil elastase activity
The present invention relates to a binding agent capable of specifically binding and competitively inhibiting neutrophil elastase, the binding agent comprising an immunoglobulin single variable domain (ISVD), as well as related products, methods and uses, for example, methods and uses, particularly for the prevention, treatment or diagnosis of inflammatory diseases.
Owner:UNIV LIEGE +2
Generation of human alpha-gal- and tick-specific IGE monoclonal antibodies for diagnostic and therapeutic use
PCT designated stageWO2026006386A1Immunoglobulins against animals/humansAllergen ingredientsRed meatHuman ige
Owner:VANDERBILT UNIV
Kit for jointly detecting phosphorylated Tau-217 and non-phosphorylated Tau-217
The invention discloses a kit for jointly detecting phosphorylated Tau-217 and non-phosphorylated Tau-217. The kit comprises a magnetic microsphere reagent, a detection antibody reagent and a fluorescent microsphere reagent, the magnetic microsphere reagent comprises a magnetic microsphere compound, the detection antibody reagent comprises a first detection antibody compound and a second detection antibody compound, and the fluorescent microsphere reagent comprises a first fluorescent microsphere compound and a second fluorescent microsphere compound. The invention provides a kit for jointly detecting phosphorylated Tau-217 and non-phosphorylated Tau-217, which is based on a single molecule detection technology, and realizes accurate distinguishing and high-sensitivity detection on the phosphorylated Tau-217 and the non-phosphorylated Tau-217 at the same time through a double-target synchronous detection design and a double-color fluorescence report system.
Owner:深圳市光与生物科技有限公司 +2
Electrochemiluminescence immunosensor for detecting interleukin-1 beta and preparation method and application thereof
The application discloses an electrochemiluminescence immunosensor for detecting interleukin-1 beta and a preparation method and application thereof, and comprises a three-electrode system of a working electrode, a reference electrode and a counter electrode; the working electrode is a modified electrode of CoAl layered double hydroxide, is loaded with platinum nanoparticles after being etched by alkali, and is obtained by fixing interleukin-1 beta antibodies and blocking non-specific sites; and a solution containing luminol is used as an electrolyte during detection of the immunosensor. The working electrode of the immunosensor takes oxygen-rich vacancy CoAl layered double hydroxide as a substrate, combines with platinum nanoparticles to realize EMSI effect, significantly enhances the electrochemiluminescence signal of a luminol-dissolved oxygen system, realizes quantitative detection of IL-1 beta by combining with specific antigen-antibody recognition, and has the characteristics of strong anti-interference ability, fast detection speed and good stability.
Owner:HANGZHOU FIRST PEOPLES HOSPITAL
EV membrane protein single molecule detection method based on droplet microfluidics and application thereof
PendingCN120591385AMicrobiological testing/measurementFluorescence/phosphorescenceCD63Molecular analysis
The invention discloses an EV membrane protein single molecule detection method based on droplet microfluidics and application thereof. The method comprises the following steps: firstly, constructing an Ab-oligo compound which is formed by sequentially connecting an antibody, Linker, Linker connection DNA, RNA capable of being specifically cut by RNA enzyme and template DNA for starting signal amplification; then capturing the extracellular vesicles in the plasma by using the CD9 / CD63 / CD81 functionalized magnetic beads; the method comprises the following steps: adding an Ab-oligo compound and a sealing buffer solution into extracellular vesicles, incubating, removing the uncombined Ab-oligo compound, adding RNA enzyme for incubating and enzyme digestion, collecting template DNA for starting signal amplification, and performing microdroplet digital PCR analysis to realize single molecule analysis of EV membrane protein. According to the invention, the one-to-one correspondence relationship between the antibody and oligonucleotide is established through Linker for the first time, single protein information is converted into single nucleic acid chain information, and EV membrane protein single molecule detection is realized. The method is simple to operate, can qualitatively and quantitatively detect the single EV membrane protein, and is beneficial to further research on the relationship between the EV membrane protein and diseases.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Reversing aging of the central nervous system
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Isolation method of bovine epidemic fever virus, and bovine epidemic fever virus obtained and application thereof
ActiveCN120249227BSsRNA viruses negative-senseViral antigen ingredientsCytopathic effectViral infection
The application discloses an isolation method of bovine epidemic fever virus and the bovine epidemic fever virus obtained by the method and application of the bovine epidemic fever virus, and belongs to the technical field of bovine epidemic fever virus isolation. The application aims to provide an efficient and rapid method for isolating bovine epidemic fever virus. The application provides the isolation method of the bovine epidemic fever virus, wherein the anticoagulated blood sample of a bovine is inoculated on KC cells for culture, the virus is harvested, the BHK-21 cells are inoculated to grow into a monolayer, and the first generation of passage cells with cytopathic effect is obtained by passage. The virus strain can also be used for screening, preparation and detection of bovine epidemic fever virus antibodies, and for preparation of an animal model infected by the bovine epidemic fever virus.
Owner:HARBIN VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER HARBIN BRANCH CENTER)
Methods for detecting RNA binding protein complexes
ActiveUS12460257B2Microbiological testing/measurementDNA preparationProtein targetImmunoprecipitation
The present disclosure relates to methods of identifying RNA targets of RNA binding proteins. In aspects, the disclosure relates to a method of identifying RNA molecules bound by RNA binding proteins. Some embodiments of the present disclosure relate to a method that can definitively identify direct RNA-target interactions with targeted proteins without the requirement for immunoprecipitation or gel extraction. In some embodiments, the method may include combining multiple antibodies in the same sample.
Owner:ECLIPSE BIOINNOVATIONS INC
Cuttable immune cell adapter
PendingCN121219014AAntibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsBiochemistryCytokine
The present invention relates to antibody-cytokine conjugates, wherein the cytokine is conjugated to the antibody via a cleavable linker. Conjugates according to the invention can be prepared by coupling a functionalized antibody Ab (F) x comprising x reactive moieties F, where x is an integer in the range of 1-10, with an immune cell-binding polypeptide comprising one or two reactive moieties Q, where the antibody is specific for tumor cells, and the immune cell-binding polypeptide is specific for immune cells, wherein the reaction forms a covalent bond between the functionalized antibody and the immune cell-binding polypeptide by reaction of Q with F. The invention further relates to antibody-cytokine conjugates obtainable by the method according to the invention and to medical uses thereof.
Owner:SYNAFFIX BV
Antibody for resisting novel coronavirus envelope protein or antigen binding fragment thereof and application of antibody or antigen binding fragment
The invention belongs to the technical field of antibodies, and discloses an antibody for resisting novel coronavirus envelope protein or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof comprises a heavy chain and a light chain; a heavy chain of the antibody or the antigen binding fragment thereof comprises: a heavy chain variable region, wherein the heavy chain variable region comprises CDR-H1, CDR-H2 and CDR-H3; a light chain of the antibody or the antigen binding fragment thereof comprises a light chain variable region, and the light chain variable region comprises CDR-L1, CDR-L2 and CDR-L3. The antibody or the antigen binding fragment thereof can be used for detecting the existence or the level of the novel coronavirus envelope protein in a sample, detecting the novel coronavirus and diagnosing diseases related to novel coronavirus infection.
Owner:ZUNYI MEDICAL UNIV ZHUHAI CAMPUS